Press Releases

Roswell Park announced that the ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data. Four studies that incorporate SurVaxM are currently underway at Roswell Park and other centers nationally.

Roswell Park has been recognized by two national organizations for its excellence as a workplace.

Dr. Candace Johnson honored with Distinguished Citizen Award from Scouting America for exemplifying the ideals of scouting through notable citizenship, leadership and values, and activity in the community.

Patients with advanced non-small cell lung cancer (NSCLC) are often treated with immunotherapy drugs known as checkpoint inhibitors, which are designed to strengthen the immune system’s ability to kill cancer cells — but these drugs do not produce a lasting response in most patients with this cancer type. Initial results of a phase 1 clinical trial of the investigational drug JNJ-86974680 reveal that it has the potential to overcome that limitation.

Researchers from Roswell Park will report their latest findings to colleagues from around the world at the 2025 annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois, April 25-30.

Roswell Park Comprehensive Cancer Center is at the forefront of a new approach to cancer treatment, called CAR T-cell therapy. The little known, but highly promising technology breakthrough makes it possible for your body to fight cancer, often without invasive surgery, offering patients new hope for the possibility of long-term remission.

Roswell Park Comprehensive Cancer Center achieved "textbook" positive outcomes for 90% of 150 consecutive minimally invasive esophagectomies (RAMIE) performed between 2020-2024, as reported in a study in the Journal of Gastrointestinal Surgery.

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to a preclinical study led by Roswell Park. Results of the study, led by Sayan Chakraborty, PhD, Assistant Professor of Oncology at Roswell Park, appear in Advanced Science.

Thomas B. Tomasi Jr., MD, PhD, who led Roswell Park as President and CEO from 1986-1996, died March 23, 2025, at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s top cancer centers.